AVITA Medical, Inc.

AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Our technologies address critical healing needs arising from burns, traumatic injuries and surgical repairs, through a portfolio of proprietary and complementary products that support wound bed preparation, definitive closure, and recovery. Our current commercial portfolio includes RECELL ( RECELL ), and two complementary wound care products, PermeaDerm and Cohealyx , which together support a comprehensive standard of care for acute wounds. At the forefront of our portfolio is RECELL, approved by the United States Food & Drug Administration (the FDA ) for the treatment of thermal burn wounds and full-thickness skin defects. While RECELL is also approved in the United States for restoring pigmentation of stable depigmented vitiligo lesions, we have paused further commercial investment in vitiligo at this time. In 2024 and 2025, we expanded our product offerings to address additional acute wound care needs. In January 2024, we entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. ( Stedical ) to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix in the United States ( U.S. ). In March 2025, we entered into a multi-year agreement to also manufacture PermeaDerm.